ReviewAdvanced healthcare materials2025
Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.
Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Development of an LC-MS/MS-Based Analytical Method, In Vitro Characterization, and Pharmacokinetic Study of Rafoxanide Nanosuspension in Sheep.Animals : an open access journal from MDPI · 2026Article
- Cellular lipids: fundamental host factors for monkeypox virus replication and pathogenesis.Archives of microbiology · 2026Review
- Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer-Aided Drug Design.International journal of microbiology · 2026Review
- AI-driven drug reposition for pathogens: a new paradigm in pandemic preparedness.Frontiers in chemistry · 2026Review
- Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics.Small science · 2026Article
- Translational potential of safe-by-design nanoengineered niclosamide in viral and cancer therapy.Materials today. Bio · 2025Article
- A Strategic Antimetastatic Solution for Bone-Targeting Prostate Cancer via Nanoengineered Niclosamide.Nano letters · 2025Review
- Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Advanced healthcare materials · 2025Review
- Nanoengineered Niclosamide as a Microenvironment Modulator for Spinal Cord Regeneration: A Hypothetical Roadmap Toward Brain/Head Transplant Feasibility.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Niclosamide, initially developed as an anthelmintic, has recently emerged as a potential antiviral, showing efficacy against diverse viral threats, including Mpox. As the global health landscape faces recurrent Mpox outbreaks, repurposing niclosamide through advanced material strategies offers promising therapeutic avenues. This article explores the antiviral mechanisms of niclosamide, focusing on how innovative nano-hybrid formulations enhance its bioavailability and pharmacological performance. By leveraging nanohybridization, niclosamide's limitations-such as poor solubility and bioavailability-are addressed, enabling targeted delivery and sustained release. Early preclinical studies reveal that niclosamide disrupts Mpox replication and entry processes, suggesting its utility as a therapeutic option against poxvirus infections. Looking forward, further in vitro, animal models, and clinical investigations are essential to optimize its application and dosing for Mpox. With continued development in advanced materials, nanohybrid niclosamide could become a critical tool in managing Mpox and related viral threats, offering an accessible, cost-effective option for outbreak preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.